Current Seminars

15/11/2011 - 18:30 - India: Marketing Yervoy for Prostate Cancer

By: Team bioLOGIC (Peter Le, Sandeep Sehgal, Hina Abbas and Jean Frederic Comeau) Large population, rapid economic growth, and talented workforce at low costs have attracted multinational companies to India. Furthermore, economic development and increasing urbanization in India has led people to adapt unhealthy Western lifestyles, and thus heart...

08/11/2011 - 18:30 - Brazil: Marketing GSK's Benlysta for Lupus

Belimumab (Benlysta®), a fully human monoclonal antibody that inhibits B-lymphocyte stimulator (BLyS) developed by Human Genome Sciences and GlaxoSmithKline (GSK), is the first lupus drug to gain FDA approval in 56 years. Benlysta® was approved by the FDA is March 2011 and is indicated for the treatment of active, autoantibody-positive,...

01/11/2011 - 18:30 - Johnson & Johnson’s Cypher drug eluting Stent: Improvement and Patent infringement

Team Inno5: Xin Hang, Jessica Morden, Faizan Rahim, Jonathan Sawatsky, Olga Vorobyova     Approximately a million coronary stent insertions are performed annually worldwide to treat coronary heart disease. Drug-eluting stents (DES) were developed to address the issues of thrombosis and restenosis associated with bare metal...

25/10/2011 - 18:30 - China: Marketing Pfizer's Sutent for Gastrointestinal Tumors

Sunitinib malate (Sutent®) is a small-molecular inhibitor of tyrosine kinase receptors produced by Pfizer. It is used in the treatment of patients with gastrointestinal stromal tumours (GIST), a rare disease that affects the gastrointestinal tract. Patients suffering from GIST who develop resistance to or do not respond to the first-line...

18/10/2011 - 18:30 - Amgen V Transkaryotic Therapies: The Legal Battle Over Recombinant Erythropoietin

The patent infringement lawsuit between Amgen and Transkaryotic Therapies (TKT) over recombinant erythropoietin, a multibillion dollar biologic, is one of the most famous intellectual property cases in biotechnology. The patent protection of Amgen’s first blockbuster product, Epogen, was threatened by TKT's comparable product Dynepo....

Pages